Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study - PubMed
4 hours ago
- #mirikizumab
- #Crohn's disease
- #quality of life
- Mirikizumab, an anti-IL23p19 antibody, showed efficacy in treating moderately to severely active Crohn's disease in a phase 2 study.
- Patients (N=191) were randomized to placebo or mirikizumab doses (200 mg, 600 mg, or 1000 mg) intravenously every 4 weeks for 12 weeks, with responders continuing treatment up to 104 weeks.
- Quality of life and patient-reported outcomes improved significantly in mirikizumab groups compared to placebo at week 12, with sustained improvements through weeks 52 and 104.
- Assessments included the Inflammatory Bowel Disease Questionnaire, 36-Item Short-Form Health Survey, Patient's Global Rating of Severity, and Abdominal Pain Numeric Rating Scale.
- The study concluded that mirikizumab treatment was associated with long-term improved quality of life and reduced disease severity in Crohn's disease patients.